These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23360455)

  • 1. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.
    Ishida T; Ito A; Sato F; Kusumoto S; Iida S; Inagaki H; Morita A; Akinaga S; Ueda R
    Cancer Sci; 2013 May; 104(5):647-50. PubMed ID: 23360455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of regulatory FoxP3
    Amakata M; Teraki Y
    Int J Dermatol; 2019 Dec; 58(12):e247-e249. PubMed ID: 31334834
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 6. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
    Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
    Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
    [No Abstract]   [Full Text] [Related]  

  • 7. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
    Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 10. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study.
    Maemoto H; Ariga T; Kusada T; Heianna J; Manabe Y; Miyakawa A; Nakachi S; Morishima S; Iraha S; Ganaha F; Masuzaki H; Murayama S
    Jpn J Clin Oncol; 2019 Feb; 49(2):153-159. PubMed ID: 30452692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
    Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
    Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
    Tanba K; Uoshima N; Uchiyama H; Kawata E; Isa R; Yamaguchi J; Tsutsumi Y; Akaogi T; Kobayashi Y; Katsura K; Kuroda J; Taniwaki M
    Ann Hematol; 2016 Mar; 95(4):661-2. PubMed ID: 26754634
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
    Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
    Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.
    Morichika K; Tomoyose T; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Nishi Y; Nakachi S; Karube KN; Fukushima T; Katoh T; Ohshima K; Masuzaki H
    Intern Med; 2016; 55(10):1345-9. PubMed ID: 27181545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
    Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
    J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
    Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.